Equities

Anhui Huaheng Biotechnology Co Ltd

Anhui Huaheng Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)110.72
  • Today's Change-1.30 / -1.16%
  • Shares traded517.61k
  • 1 Year change+52.61%
  • Beta--
Data delayed at least 15 minutes, as of Jun 08 2023 06:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anhui Huaheng Biotechnology Co Ltd is a China-based company specializing in the research and development, production and sales of amino acids and other bio-based products based on alanine series products. The Company is a high-tech enterprise focusing on synthetic biotechnology and mainly engaged in the research and development, production and sales of amino acid and its derivative products. The Company's main products include alanine series products (L-alanine, DL-alanine, β-alanine), calcium D-pantothenate and α-arbutin. The Company's products are mainly used in the fields of medicine and health products, daily chemicals, food and food additives. The Company distributes its products and services within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)1.55bn
  • Net income in CNY346.00m
  • Incorporated2005
  • Employees995.00
  • Location
    Anhui Huaheng Biotechnology Co LtdNo. 197 Chang'an Road, Gaoxin DistrictHEFEI 231031ChinaCHN
  • Phone+86 55 165689046
  • Fax+86 55 165689468
  • Websitehttp://www.huahengbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Kanion Pharmaceutical Co., Ltd.4.62bn465.92m16.34bn5.76k34.583.29--3.530.80830.80838.028.490.72814.066.10802,906.407.516.5510.069.4671.5374.4210.3110.182.13--0.002224.4219.255.8535.543.05-4.1529.67
Dizal Jiangsu Pharmaceutical Co Ltd0.00-793.80m16.90bn328.00--10.76-----1.96-1.960.003.850.00----0.00-35.78---39.81----------5.36--0.0464---100.00---9.87------
Xiamen Amoytop Biotech Co Ltd1.60bn313.74m17.29bn1.55k55.1211.59--10.800.77130.77133.943.670.95981.387.081,035,037.0018.8112.5121.7014.6188.8488.9019.5914.363.20--0.00623.7334.8636.4358.40123.3152.14--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.54bn540.78m17.40bn8.42k32.182.42--2.660.21040.21042.542.790.56692.564.88776,740.605.677.198.3111.1758.5867.1110.0111.451.4017.370.182135.84-8.642.54-82.25-12.82-0.00330.00
Anhui Huaheng Biotechnology Co Ltd1.55bn346.00m17.90bn995.0051.8311.38--11.562.202.209.8410.010.82958.037.331,556,281.0018.5017.8622.3622.2938.0538.6722.3021.491.74--0.1119.3948.6929.9790.2337.5956.88--
KPC Pharmaceuticals Inc7.83bn399.74m18.32bn5.32k45.783.58--2.340.52770.527710.426.750.85662.442.961,470,966.004.415.537.369.1642.9044.675.145.501.36--0.187834.060.34577.19-24.523.03-17.65--
China Resources Dubl-Crne Phrmctl Co Ltd9.67bn1.20bn18.67bn11.82k15.341.76--1.931.171.179.3210.160.67922.566.05817,820.008.798.8111.5811.3553.7359.8112.9411.771.91--0.024939.043.688.0324.366.6727.6948.21
Data as of Jun 08 2023. Currency figures normalised to Anhui Huaheng Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

33.06%Per cent of shares held by top holders
HolderShares% Held
Bosera Asset Management Co., Ltd.as of 31 Dec 20225.38m7.69%
E Fund Management Co., Ltd.as of 31 Dec 20224.86m6.96%
Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 20224.85m6.94%
Da Cheng Fund Management Co., Ltd.as of 31 Dec 20222.60m3.72%
China Universal Asset Management Co., Ltd.as of 31 Dec 20221.12m1.61%
Hwabao WP Fund Management Co., Ltd.as of 31 Dec 20221.11m1.59%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2022982.71k1.41%
China Post & Capital Fund Management Co., Ltd.as of 31 Dec 2022962.86k1.38%
China Asset Management Co., Ltd.as of 31 Dec 2022745.55k1.07%
GF Fund Management Co., Ltd.as of 31 Dec 2022496.71k0.71%
More ▼
Data from 31 Dec 2022 - 25 May 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.